{
    "clinical_study": {
        "@rank": "139703", 
        "arm_group": {
            "arm_group_label": "participating subject", 
            "arm_group_type": "Other", 
            "description": "Each subject receives one experimental treatment and one placebo treatment"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to test the effect of a localized narrow band ultraviolet\n      (NB-UVB) phototherapy compared to visible light that does not produce UVB on the clearance\n      of psoriasis plaques and resolution of itching.  Localized NB-UVB (Levia\u00ae) phototherapy\n      device is cleared by the U.S Food and Drug Administration (FDA)."
        }, 
        "brief_title": "Use of Localized NB-UVB (Levia\u00ae) in the Treatment of Plaque-psoriasis", 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults 18 years or older with bilateral psoriasis plaques, in  general good health as\n             determined by the Principal Investigator by medical history and physical exam.\n\n          -  Able to understand consent procedure\n\n          -  Able to comply with protocol activities\n\n          -  Must have baseline symmetric target lesions with baseline Target Lesion Score (TLS)\n             of 6 or higher (scale of 0-12), i.e., moderate in intensity for each target.\n\n        Target Lesion Scoring: Thickness, scaling and erythema of  the plaques are rated each on a\n        scale of 0-4.  The three scores are summed.  The minimum score is 0; the maximum  is 12.\n        Scores of 6 or greater are considered moderate to severe.\n\n        Exclusion Criteria:\n\n          -  Patients less than 18 years old\n\n          -  Patients not able to understand consent procedure\n\n          -  Patients unable to comply with protocol activities\n\n          -  Non-English speakers: the study assessments/questionnaires/evaluations are not\n             scientifically validated in languages other than English\n\n          -  Baseline target lesions scores of less than 6\n\n          -  Patients with a photosensitive disorder or on a medication which has been\n             demonstrated in these patients to cause photosensitivity\n\n          -  Patients receiving concomitant phototherapy to test sites\n\n          -  Patient receiving topical medication to test sites  within 2 weeks of study\n             initiation\n\n          -  Patient receiving Methotrexate, Acitretin, Cyclosporine, or other oral medications\n             for psoriasis within 4 weeks of study initiation\n\n          -  Patients receiving Etanercept (Enbrel\u00ae) within the past 2 months of study initiation\n\n          -  Patients receiving Infliximab (Remicade\u00ae), Ustekinumab (Stelara\u00ae), Golimumab\n             (Simponi\u00ae) Adalimumab (Humira\u00ae) or Alefacept (Amevive\u00ae) within the past 3 months\n             prior to study initiation\n\n          -  Receipt of an investigation agent within the past 4 weeks (or within 5 half lives)\n             prior to study ignition\n\n          -  Systemic corticosteroid therapy within the past month\n\n          -  Concurrent use of prohibited medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107482", 
            "org_study_id": "Levia"
        }, 
        "intervention": {
            "arm_group_label": "participating subject", 
            "intervention_name": "Levia NB-UVB light", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "contact": {
                "email": "ndonovan1@tuftsmedicalcenter.org", 
                "last_name": "Nicole Dumont", 
                "phone": "617-636-7462", 
                "phone_ext": "7462"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02111"
                }, 
                "name": "Dermatology Research, Tufts Medical Center"
            }, 
            "investigator": {
                "last_name": "Alice B Gottlieb, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Bilateral Comparator, Sham-Light Source Controlled, Assessor Blinded Clinical Trial of Localized Narrow Band-Ultraviolet B (NB-UVB) (Levia\u00ae) Treatment for Plaque-type Psoriasis", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The percentage of lesions with a clear or almost clear rating (target lesion score of 3 or less) on target lesion scoring at week 12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107482"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage changes in target lesion score", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Changes in target lesion pruritus Visual Analog Scale (VAS) at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Tufts Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tufts Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}